Syngenta Settles Paraquat Parkinson’s Disease Lawsuit Ahead of Philadelphia Trial

Paraquat manufacturer Syngenta has reportedly finalized a settlement agreement just before the start of what would have been the first bellwether trial in the Paraquat litigation. The lawsuit, which alleged a connection between Paraquat exposure and retired landscaper Bill Merten’s Parkinson’s disease diagnosis, was scheduled to begin last week in Philadelphia. This settlement follows Syngenta’s pattern of resolving Paraquat-related claims before they reach the trial stage.

Paraquat and Alleged Parkinson’s Disease Link

Paraquat dichloride has been a widely utilized herbicide in American agriculture since it was first introduced in 1962 under the brand name Gramoxone. Farmers across the United States apply this powerful chemical to eliminate unwanted broadleaf weeds and grasses before planting various crops, including soybeans, cotton, corn, grapes, pistachios, and peanuts. Additionally, some agricultural workers use it as a desiccant to dry plants before harvest.

Despite Paraquat’s effectiveness as a weed killer, serious concerns have been raised about Paraquat safety due to its extreme toxicity. The herbicide’s alleged dangers have prompted numerous countries worldwide to implement bans on its use, though it remains legal in the United States under restricted conditions. The Environmental Protection Agency (EPA) classifies Paraquat as a “restricted use pesticide,” meaning only certified applicators with specialized training can purchase and use it.

The primary concern that has fueled litigation against Syngenta involves alleged links between Paraquat exposure and the development of Parkinson’s disease, a progressive neurological disorder affecting movement. Scientific research dating back more than a decade has suggested potential connections between this chemical and neurological damage, particularly among those with occupational exposure, such as farmers, landscapers, and agricultural workers.

Bill Merten’s Lawsuit and Settlement Details

According to his Paraquat lawsuit, Bill Merten, now 77 years old, operated a landscaping business throughout the 1980s and 1990s, during which time he regularly mixed and sprayed Paraquat as part of his professional duties. Despite wearing recommended protective clothing and equipment, Merten allegedly experienced exposure through inhalation and skin contact. His lawsuit states that he received a Parkinson’s disease diagnosis in 2021.

The Paraquat trial in Philadelphia would have represented the first public examination of evidence regarding Paraquat’s alleged connection to Parkinson’s disease, providing insight into how juries might respond to scientific evidence and corporate documents related to Paraquat safety.

However, just as proceedings were set to begin, Syngenta reportedly reached a settlement agreement with Merten. While the specific terms remain confidential, this resolution follows Syngenta’s consistent approach of settling Paraquat-related lawsuits before trial. In one previous instance, the company reportedly paid over $187 million to resolve a single multi-plaintiff claim.

Thousands of Paraquat Lawsuits Filed

Merten’s Paraquat lawsuit represents just one of thousands of similar legal actions filed against Syngenta and Chevron, which distributed Paraquat products manufactured by Syngenta until 1986. Currently, more than 6,400 Paraquat lawsuits are pending in the federal court system, with additional claims proceeding at the state level.

The federal lawsuits have been consolidated into a multidistrict litigation (MDL) in the Southern District of Illinois under U.S. District Judge Nancy Rosenstengel. This consolidation, established in June 2021, allows for coordinated discovery and pretrial proceedings while preserving each plaintiff’s right to an individual trial.

Paraquat Studies and Regulatory Status

The scientific community continues to investigate the alleged connection between Paraquat exposure and Parkinson’s disease. Multiple studies have suggested that individuals exposed to this herbicide may face an elevated risk of developing the neurological condition, though the exact mechanism remains under investigation.

Allegations Raised in Paraquat Parkinson’s Disease Lawsuits

Plaintiffs in Paraquat litigation raised similar allegations that Syngenta and Chevron failed to adequately warn users about the potential neurological risks associated with the herbicide. These lawsuits claim that the manufacturers knew or should have known about research linking Paraquat to Parkinson’s disease, but did not provide sufficient warnings.

Both Syngenta and Chevron have consistently denied liability. Syngenta maintains that there is no credible evidence establishing a causal connection between Paraquat and Parkinson’s disease. Chevron argues that, as a former distributor that ended its relationship with the product in 1986, it should not bear responsibility in the litigation.

The Future of Paraquat Regulation and Litigation

For individuals with pending Paraquat Parkinson’s disease claims, these pre-trial settlements may signal a path toward resolution without lengthy trials. The resolution of this latest Paraquat lawsuit represents another chapter in the ongoing litigation, but many questions remain unanswered about the herbicide’s future in American agriculture and the future of thousands of pending legal claims.